Clofazimine does not lead to significant QT interval prolongation: a multicentre study
Eur Respir J
.
2018 Nov 1;52(5):1801386.
doi: 10.1183/13993003.01386-2018.
Print 2018 Nov.
Authors
Sanne M H Zweijpfenning
1
,
Hester van Groningen
1
,
Jakko van Ingen
2
,
Cecile Magis-Escurra
1
,
Martin J Boeree
1
,
Dirk Wagner
3
,
Hannelore Bax
4
,
Claire Andrejak
5
,
Reinier Wener
6
,
Ananna Rahman
7
,
Heinke Kunst
8
,
Natalie Lorent
9
,
Marc A Brouwer
10
,
Wouter Hoefsloot
1
;
NTM-NET
Affiliations
1
Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
2
Dept of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
3
Dept of Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany.
4
Dept of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
5
Dept of Pulmonary Diseases, Centre Hospitalier Universitaire Amiens, Amiens, France.
6
Dept of Pulmonary Diseases, Utrecht University Medical Center, Utrecht, The Netherlands.
7
Dept of Respiratory Medicine, Bart's Hospital, London, UK.
8
Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK.
9
Dept of Pulmonary Diseases, University Hospitals Leuven, Leuven, Belgium.
10
Dept of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
PMID:
30385602
DOI:
10.1183/13993003.01386-2018
No abstract available
Publication types
Letter
Comment
MeSH terms
Arrhythmias, Cardiac
Clofazimine*
Diarylquinolines
Heart
Humans
Long QT Syndrome*
Substances
Diarylquinolines
bedaquiline
Clofazimine